Read More

Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck’s Pneumococcal Shots – Analyst Says

The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. Market dynamics are shifting towards adults, potentially doubling with the US discussing vaccination age reduction. Prevnar20 dominates with 97% market share in adults, but Vaxcyte's advanced conjugate capabilities present a competitive advantage.

MRK

Read More

Norfolk Southern’s $600M Agreement To Solve East Palestine Derailment Is A Negative, Says Analyst

RBC analyst Walter Spracklin maintains a Sector Perform rating for Norfolk Southern Corp , setting a $270 price target. Norfolk Southern reported Q1 FY24 revenues of $3.004 billion and an adjusted EPS of $2.49. The company reaffirms its guidance for operating ratio improvement and anticipates significant changes under new management.

NSC